Antibiotic trial aims to stop COPD attacks by targeting hidden fungus
NCT ID NCT07665359
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a 4-week course of the antibiotic TMP-SMX (Bactrim) can reduce the number of serious COPD flare-ups in people whose lungs carry Pneumocystis jirovecii, a common fungus. Researchers will compare the antibiotic to a placebo in 630 adults with advanced COPD who have had at least one flare-up in the past year. Participants will be followed for one year to track flare-ups and lung function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trimethoprim-Sulfamethoxazole (TMP-SMX), also known as Bactrim or Sulfatrim
What this could lead to
If it works, this could point toward a new way to prevent COPD flare-ups by treating a hidden infection in the lungs.
What could go wrong
This is an early-stage trial with no phase assigned, so results are uncertain. The antibiotic may not clear the fungus or reduce flare-ups, and could cause side effects like allergic reactions or antibiotic resistance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiaxing University
Jiaxing, Zhejiang, China
Contact
-
First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
Contact
-
First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
Contact Email: •••••@•••••
-
Huzhou Central Hospital
Huzhou, Zhejiang, China
Contact
-
Lishui hospital of Zhejiang University
Lishui, Zhejiang, China
Contact
-
Red Cross Hospital, Hangzhou, China
Hangzhou, Zhejiang, China
Contact
-
Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Contact
-
Shanghai Pulmonary Hospital, Shanghai, China
Shanghai, Shanghai Municipality, China
Contact
-
Shanghai Tongji Hospital, Tongji University School of Medicine
Shanghai, Shanghai Municipality, China
Contact
-
Shaoxing People's Hospital
Shaoxing, Zhejiang, China
Contact
-
Sir Run Run Shaw Hospital
Hangzhou, Zhejiang, China
Contact
-
Taizhou Hospital
Taizhou, Zhejiang, China
Contact
-
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
Taizhou, Zhejiang, China
Contact
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Contact
-
The Sixth Affiliated Hospital of Wenzhou Medical University
Lishui, Zhejiang, China
Contact
-
Tongji Hospital
Wuhan, Hubei, China
Contact
-
West China Hospital
Chengdu, Sichuan, China
Contact
-
Zhejiang Hospital
Hangzhou, Zhejiang, China
Contact
-
Zhejiang Quhua Hospital
Quzhou, Zhejiang, China
Contact
-
Zhejiang Rongjun Hospital
Jiaxing, Zhejiang, China
Contact